Development
Cytokinetics, Incorporated
CYTK
$36.16
-$0.42-1.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 7.53M | 7.82M | 9.95M | 11.05M | 7.59M |
| Total Other Revenue | -- | 0.00 | 0.00 | 87.00M | 87.00M |
| Total Revenue | 7.53M | 7.82M | 9.95M | 98.05M | 94.59M |
| Cost of Revenue | 330.12M | 320.17M | 300.37M | 274.30M | 240.81M |
| Gross Profit | -322.59M | -312.35M | -290.42M | -176.25M | -146.23M |
| SG&A Expenses | 173.61M | 183.47M | 191.58M | 194.57M | 177.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 503.74M | 503.63M | 491.95M | 468.87M | 418.79M |
| Operating Income | -496.21M | -495.82M | -481.99M | -370.82M | -324.20M |
| Income Before Tax | -526.24M | -526.73M | -539.62M | -430.80M | -388.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -526.24 | -526.73 | -539.62 | -430.80 | -388.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -526.24M | -526.73M | -539.62M | -430.80M | -388.96M |
| EBIT | -496.21M | -495.82M | -481.99M | -370.82M | -324.20M |
| EBITDA | -484.31M | -488.60M | -475.22M | -364.50M | -318.39M |
| EPS Basic | -5.45 | -5.52 | -5.69 | -4.58 | -4.25 |
| Normalized Basic EPS | -3.41 | -3.45 | -3.41 | -2.71 | -2.49 |
| EPS Diluted | -5.45 | -5.52 | -5.69 | -4.58 | -4.25 |
| Normalized Diluted EPS | -3.41 | -3.45 | -3.41 | -2.71 | -2.49 |
| Average Basic Shares Outstanding | 386.06M | 381.67M | 379.36M | 369.33M | 359.17M |
| Average Diluted Shares Outstanding | 386.06M | 381.67M | 379.36M | 369.33M | 359.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |